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Abstract
Background: Recently we developed and validated generic quality indicators that define ‘appropriate antibiotic
use’ in hospitalized adults treated for a (suspected) bacterial infection. Previous studies have shown that with
appropriate antibiotic use a reduction of 13% of length of hospital stay can be achieved. Our main objective in this
project is to provide hospitals with an antibiotic checklist based on these quality indicators, and to evaluate the
introduction of this checklist in terms of (cost-) effectiveness.
Methods/Design: The checklist applies to hospitalized adults with a suspected bacterial infection for whom
antibiotic therapy is initiated, at first via the intravenous route. A stepped wedge study design will be used,
comparing outcomes before and after introduction of the checklist in nine hospitals in the Netherlands. At least
810 patients will be included in both the control and the intervention group. The primary endpoint is length of
hospital stay. Secondary endpoints are appropriate antibiotic use measured by the quality indicators, admission to
and duration of intensive care unit stay, readmission within 30 days, mortality, total antibiotic use, and costs
associated with implementation and hospital stay. Differences in numerical endpoints between the two periods will
be evaluated with mixed linear models; for dichotomous outcomes generalized estimating equation models will be
used. A process evaluation will be performed to evaluate the professionals’ compliance with use of the checklist.
The key question for the economic evaluation is whether the benefits of the checklist, which include reduced
antibiotic use, reduced length of stay and associated costs, justify the costs associated with implementation
activities as well as daily use of the checklist.
Discussion: If (cost-) effective, the AB-checklist will provide physicians with a tool to support appropriate antibiotic
use in adult hospitalized patients who start with intravenous antibiotics.
Trial registration: Dutch trial registry: NTR4872
Keywords: Checklist, Antibiotics, Implementation, Quality indicators, Stepped-wedge design
Background
The need to improve antibiotic use
The increasing antimicrobial resistance rate is one of the
most important health care problems at this moment. The
total consumption of antibiotics is the main driving force
[1,2]. The World Health Organization signalled the emer-
gence of antimicrobial resistance (AMR), along with the
steady decline in the discovery of new antimicrobials, as a
major health threat for the coming decade. To help con-
trol AMR, a better use of the current agents is necessary
[3]. Recent studies have shown considerable room for im-
provement in the two most common bacterial infections:
respiratory and urinary tract infections [4,5]. An important
question is how to achieve such an improvement.
Previous studies have shown that appropriate antibiotic
use is not only of great importance to curb antimicrobial
resistance, but also has a short-term consequence. The
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evaluation of antibiotic treatment for urinary tract in-
fections in hospitals showed an inverse relationship be-
tween the proportion of appropriate antibiotic use in a
patient and length of stay (LOS). Prescribing therapy in
accordance with local hospital guidelines was associated
with a shorter LOS (7.3 days vs. 8.7 days; P = 0.024) [6].
Recently a similar inverse relationship has been shown
between appropriate antibiotic use in treatment of all
bacterial infections in the hospital and LOS, with a re-
duction of 13% in LOS with appropriate use. [Abstract
poster: Quality Indicators for Monitoring Appropriate
Antibiotic Use in Hospitals: an Important Tool for Anti-
biotic Stewardship. K-325. 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy, September 5 -9,
2014, Washington DC].
Quality indicators
Guidelines defining appropriate antimicrobial treatment
are available. To measure whether guideline recommen-
dations are implemented in daily practice, an instrument
is needed that validly measures the quality of antibiotic
use in daily clinical practice. Guideline-based quality in-
dicators (QIs) are such tools. Recently, generic QIs for
the antimicrobial treatment of bacterial infections in
hospitals have been developed and validated [7]. The
challenge is the embedding of appropriate antibiotic use,
as defined by these QIs, in daily practice.
Checklist
A checklist can be a tool for implementation; since it has
been shown in other high-risk disciplines that adherence
to checklists increases safety [8]. This also holds true for
the field of medicine. For example, in surgery, implementa-
tion of a comprehensive multidisciplinary SURgical PAtient
Safety System (SURPASS) is associated with an absolute
risk reduction in surgical complications of 10.6% [9]. Simi-
larly, the introduction of a checklist to improve patient care
among gynaecologic oncology patients has resulted in a de-
creased length of stay of one day (4.5 days in the pre- and
3.5 days in the post-implementation period (P = 0.007))
[10]. In the field of infectious diseases, Pronovost et al.
showed that introduction of a five-points checklist to re-
duce infections when inserting a central venous catheter,
resulted in a decrease of the median rate of infections from
2.7 per 1,000 patients to zero after three months [11].
We hypothesize that an antibiotic checklist, to be used
at the start of antibiotic treatment and after 48-72 hours
of treatment, will improve clinical patient care, reduce
costs and will ultimately contribute to the containment
of antimicrobial resistance.
Objectives
This study is set to implement an antibiotic checklist based
on the validated generic quality indicators measuring the
appropriateness of intravenously initiated antibiotic use in
hospitalized adults treated for a suspected bacterial infec-
tion, and to analyse the effect of the introduction of the
checklist on patient care in terms of shorter duration of in-
tensive care unit (ICU)- and hospital stay, adequate treat-
ment, decreased mortality rates, decreased total antibiotic
use and lower costs.
Methods and design
Phase 1: The AB-checklist and barriers for use
The ‘Development of reliable generic quality indicators
for the optimization of antibiotic use in the hospital’
(RIANT)-study used a RAND modified Delphi method
to develop a set of generic QIs for appropriate antibiotic
use in the treatment of all bacterial infections in hospi-
talized adult patients [7]. The clinimetric properties of
these QIs have been tested in 1,890 hospitalized pa-
tients, in 22 Dutch hospitals. This analysis resulted in
eight useful QIs, of which seven were process indicators
that focus on the actual care provided. The antibiotic
checklist includes these seven QIs.
The antibiotic checklist is intended as a reminding tool
for the physician who starts intravenous (IV) antibiotic
treatment. It is actually divided into two bundles (Figure 1).
The first bundle has to be completed at the moment of
prescribing IV antibiotics, and comprises five items. The
second bundle is used during the course of treatment, at
the latest after 72 hours of treatment. This part consists of
two items.
As a preparation, we identified barriers of implement-
ing this checklist, using a questionnaire based on an in-
strument of the Netherlands Organization for Applied
Scientific Research (TNO), which is designed to survey
determinants that influence the uptake of an innovation
in health care organizations [12,13]. The questionnaire
was sent to specialists and residents who work at the
participating hospitals. Based on the identified barriers,
the checklist design and its implementation format
were adapted.
Phase 2: cluster randomized clinical trial to evaluate the
AB-checklist
Study design and setting
The (cost-) effectiveness of introducing the antibiotic
checklist will be studied in a controlled, multicentre, pro-
spective study using a stepped wedge design, comparing
outcomes before and after implementation of the checklist
while accounting for potential confounders [14].
The checklist will be introduced in nine hospitals over
four time periods, during a total study period of eleven
months (Figure 2). The aim is to include at least 810 pa-
tients in the period before- (the baseline group), and at
least 810 patients with a completed checklist in the
period after checklist introduction (intervention group).
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During the transition period implementation activities
will be started and no patients will be included. This
period runs from one month before introduction of the
checklist to one week after introduction. Since compli-
ance to the checklist will not be 100%, we will also col-
lect data concerning the LOS from the patients in whom
the checklist should have been but was not completed
during the period after checklist introduction (the spill
over group).
To promote selection of a patient population repre-
sentative for every day clinical practice in the
Netherlands, two university hospitals and seven teach-
ing hospitals will participate, and in each hospital at
least one surgical and one non-surgical ward will be
Phase 1: the start of antibiotic 
treatment intravenously
Yes No
1 Take at least two sets of 
blood cultures before 
starting systemic antibiotic 
therapy
In my opinion, not necessary with this diagnosis
Cultures have been taken < 1 week ago
…………………………………………………….
2 Take specimens for culture 
from suspected sites of 
infection
No culture possible 
Cultures have been taken < 1 week ago
…………………………………………………….
3 Prescribe systemic 
antibiotic treatment 
according to the local 
antibiotic guideline
According to other guidelines, namely ………..
Allergy
Treatment based on previous culture results
.      …………………………………………………….
4 a. Determine renal function …   …………………………………………………....
b. Adapt dose and dosing 
interval of systemic 
antibiotics to renal function 
Not applicable 
…………………………………………………….
5 Document the indication for 
the antibiotic treatment in 
the case notes or electronic 
medical record (EMR).
…………………………………………………….
Phase 2: after 48-72 hours of 
treatment
Yes No
6 Adapt therapy when culture 
results become available.
…  …………………………………………………….
7 Switch from intravenous to 
oral antibiotic therapy after 
48-72 hours
Insufficient clinical improvement
No available oral antibiotic
No oral therapy possible with the diagnosis……
……………………………………………………….
Figure 1 The antibiotic checklist.
Hospital 3+4
Hospital
5+6+7
Hospital 8+9
Hospital 1+2
Nov-14 Sep-15
1-12-2014 1-1-2015 1-2-2015 1-3-2015 1-4-2015 1-5-2015 1-6-2015 1-7-2015 1-8-2015 1-9-2015
Nov-14 - Mar-15
Baseline
Nov-14 - Jan-15
Baseline
Nov-14 - May-15
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Mar-15 - Sep-15
Intervention
May-15 - Sep-15
Intervention
Dec - Jan
Transition
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Transition
Jul-15 - Sep-15
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Transition
Jan-15 - Sep-15
Intervention
Jun - Jul
Transition
Nov-14 - Nov-14
Baseline
Figure 2 The stepped wedge design for checklist implementation.
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included. The ICU and the paediatric ward will be ex-
cluded, as the quality indicators do not apply to these
populations. Patients with a suspected bacterial infec-
tion presenting on the emergency department (ED) will
be included if they are going to be hospitalized on one
of the participating wards.
Intervention
The study coordinator will design a project plan together
with the local project leader. This plan will focus on
physicians, nurses and medical students who are in-
volved in patient care. The plan will include standard
items (see Table 1), but additional items can be added, if
locally required, to cover practical issues as for example:
How do we arrange that for each patient starting with
antibiotics intravenously a checklist is filled in? How do
we arrange that the checklist does not get lost?
Patient enrolment
Eligible patients
The physician will use the checklist in all hospitalized
adults (≥18 years old), or adults at the ED who will be
admitted at a participating ward, with a suspected
community-acquired and/or hospital-acquired bacterial
infection, and will be treated with intravenous antibi-
otics. The treating physician identifies these patients
upon prescription of antibiotic therapy. The patients in-
cluded in the study are all patients that meet the above
mentioned inclusion criteria, whether they have a com-
pleted checklist or not (see Figure 3 for the flowchart).
They will be included in each hospital using an overview
of the patients who started with intravenous antibiotics.
This overview will be generated by the local depart-
ments of hospital pharmacy from the computerized
physician order entry systems. Patients are excluded
from the study in case of anticipated hospital stay of less
than 24 hours, antibiotics used as prophylaxis or
intended for less than 24 hours, hospitalization at the
ICU at the start of the treatment, transfer from another
hospital, or antibiotic treatment in the ambulance be-
fore presentation at the ED.
Primary and secondary endpoints
The primary endpoint is length of hospital stay in days.
LOS in community-acquired infections will be defined
as the number of days between admission and discharge.
In hospital-acquired infections LOS will be defined as
the number of days between start of antibiotic treatment
and discharge. Secondary endpoints are appropriate anti-
biotic treatment according to the generic QIs (yes/no
per QI and sum score of all QIs) [6], admission to and
duration of ICU stay in days, readmission within 30 days,
mortality in the hospital and in the first 30 days after
discharge, total antibiotic use, costs of hospital stay and
costs associated with implementation.
Assessments
For patient outcome we will collect data concerning the
LOS, admission to and duration of ICU stay, readmis-
sion within 30 days and mortality in hospital or within
30 days after discharge for the baseline group and the
intervention group. Furthermore we will collect data for
possible confounders of patient’s outcome, namely age,
sex, community-or hospital acquired infection, Charlson
comorbidity index [15,16], use of antibiotics during the
previous 30 days, and clinical condition as assessed by
the Modified Early Warning System [17]. To calculate
QI performance we will collect data concerning the
number of taken blood cultures including its results, the
number of taken cultures of suspected sides of infection
including its results, antibiotic use including dose, inter-
val and duration of treatment in days, the (suspected)
type of infection and relevant laboratory parameters. For
the spill over group, we will only collect data concerning
the LOS and the possible confounders.
Antibiotics included in the study belong to group J01
(antimicrobials for systemic use) of the Anatomic Thera-
peutic Chemical (ATC) classification system. When mul-
tiple antibiotics are prescribed to one patient, all antibiotics
will be registered. Antiviral therapy, medication for tuber-
culosis, antibiotics used for non-systemic selective intes-
tinal decontamination and antibiotics used as pro-kinetics
will be excluded.
Table 1 Description of activities to stimulate use of the antibiotic checklist
Activity Details For whom When or how
Education, including feedback About the need of appropriate antibiotic use and the
room for improvement in current antibiotic use based
on the baseline measurement; About the guidelines,
adaption to renal function and IV-oral switch.
Physicians, medical students Kick-off meeting;
Website, e-learning
Reminders Laminated pocket versions; posters Physicians During the whole
intervention period
Involvement of the whole
health care team
Involvement of a supervisor of each participating
department in the implementation process
Physicians Prior to implementation and
during implementation
Informing nurses about the study project Nurses e-mail, website, e-learning
Informing medical students about the study project Medical students Letter, website, e-learning
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Sample size
The power analysis is based on previous results of ap-
propriate antibiotic use on length of stay as described at
‘background’ [6,7]. In a simulation study based on the
stepped wedge design, with nine hospitals each contrib-
uting 180 patients with a suspected infection, we esti-
mated the power to approximate 80% to demonstrate a
significant reduction of 13% in length of stay, assuming
that the intraclass correlation coefficient does not exceed
0.20. With each hospital contributing 180 patients with
a suspected infection, the total sample size will be 1620
patients. For each hospital we have determined a mini-
mum number of patients in the baseline group and
intervention group, depending on the randomization
order of the hospital in the stepped wedge.
Analysis
Effect evaluation
We will use mixed linear models to analyse the overall
effect of the introduction of the checklist on length of
stay. Therefore we will evaluate differences between
baseline (before introduction of the checklist) and
intervention plus spill over (after introduction of the
checklist) (intention to treat analysis). We will also de-
termine the theoretical effect of the checklist on LOS by
evaluating differences between baseline and intervention
data without the spill over data (per protocol analysis).
Differences between the baseline data and the intervention
data for secondary outcomes will also be evaluated with
mixed linear models. For dichotomous outcomes (mortal-
ity), the comparison will be evaluated with a similar ap-
proach, using generalized estimating equation models.
These mixed models account for within-cluster dependen-
cies, and allow adjustment for possible confounders. To
assess whether differences between these groups may be
explained by confounding patient characteristics, we
will first test with multivariate multilevel (linear mixed)
analyses if these variables have a significant effect (p <
0.05) on the outcomes. Hereafter, we will compute the
estimate of the total causal effect of checklist implemen-
tation on the outcomes before and after adjusting for a
significant variable. If the estimate varies 10% or more,
possible confounding is present and in that case we will
adjust for this variable.
Figure 3 Flowchart of the included patient in our study.
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Validation and process evaluation
We will evaluate the physicians’ compliance with the
checklist. Firstly we will check whether the ticks in the
completed checklists are in accordance with the per-
formance in clinical practice. Secondly we will determine
the percentage of eligible patients for whom the check-
list has been used after checklist introduction. The num-
ber of patients in whom the checklist was actually used
(the intervention group) will be divided by the number
of patients in whom it should have been used (the inter-
vention plus the spill over group).
Economic evaluation
The key question for the economic evaluation is whether
the benefits of using the checklist, which will likely in-
clude reduced antibiotic use, reduced length of stay and
associated costs, justify the costs associated with imple-
mentation activities as well as daily use of the checklist.
For reasons of feasibility, the cost analysis will only in-
clude a few main cost drivers of health care utilization,
namely LOS on a general or ICU ward and antibiotic
use. Unit costs for health care utilization will be esti-
mated according to the Dutch guideline on (unit) cost-
ing in health care [18]. LOS and ICU stay will be valued
based on the guideline prices. Furthermore, we will com-
pare the total antibiotic use in days per antibiotic class in
the baseline and the intervention group. Antibiotic costs
will not be valued because the benefits become more evi-
dent in terms of reduced quantities rather than their
particular costs. Implementation costs will be divided in
non-recurring and recurring costs. Non-recurring costs
are related to our study, such as costs of the development
of the materials, the implementation strategy and costs of
evaluation of the implementation. Recurring costs are the
costs of accomplishment of the implementation strategy.
The primary analysis is a cost-effectiveness analysis, with
the incremental cost-effectiveness ratio expressed as the
implementation related costs per reduction of length of
stay in days. As we hypothesize that an effective imple-
mentation of the checklist will result in reduced health
care use and thus lower costs, we will also perform a cost-
benefit analysis, evaluating whether the implementation
costs are offset by this cost reduction (costs of implemen-
tation < health care cost reduction). Robustness of the re-
sults for uncertainty in the assumptions will be evaluated
in sensitivity analyses, including estimates of unit costs
and volume of implementation activities (considering less
activities will be needed if checklists become part of stand-
ard care). In a budget impact analysis results from the eco-
nomic evaluation will be extrapolated to the national level
to estimate the total clinical and budget impact in terms
of health benefits, reduction in antibiotic use, and associ-
ated economic impact on the health care budget per
annum for the Netherlands. The budget impact analysis
will be performed according to the criteria provided by
Mauskopf et al. [19], from a societal perspective as well as
from the health insurance and/or national health care
budgeting framework perspective. We will evaluate the
impact of varying implementation rates, comparing care
as usual (0% implementation), potential impact (100% im-
plementation), and the probable rates of 85% and 50%
implementation.
Ethical considerations
The project proposal was discussed with the Medical Ethics
Research Committee of the Academic Medical Centre.
They confirmed that the Medical Research Involving
Human Subjects Acts does not apply to this study and that
an official approval by the committee was not required, be-
cause patients will receive treatment according to standard
care, and will have no burden of checklist use.
Discussion
This study protocol describes the design, implementa-
tion and evaluation of the AB-checklist study. To our
knowledge, no other published studies or ongoing trials
(http://apps.who.int/trialsearch/) investigate the imple-
mentation of a generic antibiotic checklist to be used
for suspected bacterial infections in the hospital. If
(cost) effective, the AB-checklist will provide physi-
cians with a tool to support appropriate antibiotic use
in adult hospitalized patients who start intravenous
antimicrobials.
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